Data on trends in antimicrobial resistance and decreased susceptibility in gonococcal infection in England and Wales.
Ref: PHE publications gateway number: 2016433 PDF, 523KB, 45 pages
Ref: PHE publications gateway number 2015470 PDF, 966KB, 37 pages
Ref: PHE publications gateway number 2014442 PDF, 773KB, 33 pages
This file may not be suitable for users of assistive technology. Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email email@example.com. Please tell us what format you need. It will help us if you say what assistive technology you use.
Surveillance of antimicrobial resistance is critical in guiding national treatment guidelines to ensure appropriate patient management. The Gonococcal resistance to antimicrobial surveillance programme (GRASP), a national sentinel surveillance programme, was established in 2000 to monitor trends and drifts in susceptibility to antimicrobial agents used for the treatment of gonorrhoea in England and Wales.
The ongoing emergence of resistance to antimicrobials used to treat gonorrhoea is a global public health concern. The ability of gonorrhoea to successively develop resistance to different antimicrobials has hampered control efforts and gonorrhoea is at risk of becoming untreatable.
Public Health England reports annually on drug resistance and decreased susceptibility in gonorrhoea in England and Wales and has twice provided data which directly influenced changes in treatment guidelines. The current treatment strategy in the UK (and in other countries) has been to adopt a more aggressive approach of dual therapy with injectable ceftriaxone and oral azithromycin.
Previous GRASP reports are available from the National Archives website.